Sabrina Heynckes et al. described significant differences in PD-L1 expression between primary and recurrent glioblastomas, where PD-L1 expression levels were higher in de novo tumors than in relapses at both the protein and mRNA levels. Here, CD274 is linked to glioblastoma.